📰 Cochlear Limited News
Page 7 - Cochlear Limited News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Cochlear Limited. Real-time updates on events, politics, business and more.
June 22, 2023
The Competition and Markets Authority said the full merger of Cochlear and Oticon Medical ‘could reduce innovation and quality’.
June 19, 2023
MONTPELLIER, France--(BUSINESS WIRE)--Jun 19, 2023--
June 6, 2023
We compare the performance of 5 popular ASX growth shares against the S&P/ASX 200 Index (ASX: XJO) and All Technology Index (ASX: XTX).
June 3, 2023
ASX dividend stocks are the way to go in today's economy, and defensive market sectors like industrials are best, says broker Morgan Stanley.
May 29, 2023
Cochlear Limited (OTCMKTS:CHEOY – Get Rating) was the target of a large decrease in short interest in May. As of May 15th, there was short interest totalling 1,300 shares, a decrease of 48.0% from the April 30th total of 2,500 shares. Based on an average daily trading volume, of 3,400 shares, the short-interest ratio is […]
May 11, 2023
Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, is pleased to announce its participation in the
May 11, 2023
For traders looking to invest in Australian stocks, we have picked out the best health stocks to buy in 2023.
May 9, 2023
NEW YORK, May 9, 2023 /PRNewswire/ -- As per Facts and Factors study, the global cochlear implants market size was worth around USD 1.45 billion in 2022 and is predicted to grow to around USD
May 6, 2023
Cochlear Limited (OTCMKTS:CHEOY – Get Rating)’s share price traded up 1.6% during mid-day trading on Friday . The stock traded as high as $83.50 and last traded at $83.50. 838 shares traded hands during mid-day trading, a decline of 79% from the average session volume of 3,957 shares. The stock had previously closed at $82.20. […]
May 3, 2023
Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces that the Company's shareholders